Literature DB >> 9813003

Familial mutations and the thermodynamic stability of the recombinant human prion protein.

W Swietnicki1, R B Petersen, P Gambetti, W K Surewicz.   

Abstract

Hereditary forms of human prion disease are linked to specific mutations in the PRNP gene. It has been postulated that these mutations may facilitate the pathogenic process by reducing the stability of the prion protein (PrP). To test this hypothesis, we characterized the recombinant variants of human PrP(90-231) containing point mutations corresponding to Gerstmann-Straussler-Scheinker disease (P102L), Creutzfeld-Jakob disease (E200K), and fatal familial insomnia (M129/D178N). The first two of these mutants could be recovered form from the periplasmic space of Escherichia coli in a soluble form, whereas the D178N variant aggregated into inclusion bodies. The secondary structure of the two soluble variants was essentially identical to that of the wild-type protein. The thermodynamic stability of these mutants was assessed by unfolding in guanidine hydrochloride and thermal denaturation. The stability properties of the P102L variant were indistinguishable from those of wild-type PrP, whereas the E200K mutation resulted in a very small destabilization of the protein. These data, together with the predictive analysis of other familial mutations, indicate that some hereditary forms of prion disease cannot be rationalized using the concept of mutation-induced thermodynamic destabilization of the cellular prion protein.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9813003     DOI: 10.1074/jbc.273.47.31048

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  52 in total

1.  Protein engineering as a strategy to avoid formation of amyloid fibrils.

Authors:  V Villegas; J Zurdo; V V Filimonov; F X Avilés; C M Dobson; L Serrano
Journal:  Protein Sci       Date:  2000-09       Impact factor: 6.725

Review 2.  The molecular pathology of CJD: old and new variants.

Authors:  G S Jackson; J Collinge
Journal:  Mol Pathol       Date:  2001-12

3.  The role of dimerization in prion replication.

Authors:  Peter Tompa; Gábor E Tusnády; Peter Friedrich; István Simon
Journal:  Biophys J       Date:  2002-04       Impact factor: 4.033

Review 4.  Protein aggregation in disease: a role for folding intermediates forming specific multimeric interactions.

Authors:  Arthur Horwich
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

5.  Multiple substitutions of methionine 129 in human prion protein reveal its importance in the amyloid fibrillation pathway.

Authors:  Sofie Nyström; Rajesh Mishra; Simone Hornemann; Adriano Aguzzi; K Peter R Nilsson; Per Hammarström
Journal:  J Biol Chem       Date:  2012-06-05       Impact factor: 5.157

6.  Sequence determinants of amyloid fibril formation.

Authors:  Manuela López de la Paz; Luis Serrano
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-22       Impact factor: 11.205

7.  Conformational diversity in prion protein variants influences intermolecular beta-sheet formation.

Authors:  Seungjoo Lee; Lizamma Antony; Rune Hartmann; Karen J Knaus; Krystyna Surewicz; Witold K Surewicz; Vivien C Yee
Journal:  EMBO J       Date:  2009-11-19       Impact factor: 11.598

8.  Microsecond unfolding kinetics of sheep prion protein reveals an intermediate that correlates with susceptibility to classical scrapie.

Authors:  Kai-Chun Chen; Ming Xu; William J Wedemeyer; Heinrich Roder
Journal:  Biophys J       Date:  2011-09-07       Impact factor: 4.033

9.  Ligand binding promotes prion protein aggregation--role of the octapeptide repeats.

Authors:  Shuiliang Yu; Shaoman Yin; Nancy Pham; Poki Wong; Shin-Chung Kang; Robert B Petersen; Chaoyang Li; Man-Sun Sy
Journal:  FEBS J       Date:  2008-11       Impact factor: 5.542

Review 10.  The consequences of pathogenic mutations to the human prion protein.

Authors:  Marc W van der Kamp; Valerie Daggett
Journal:  Protein Eng Des Sel       Date:  2009-07-14       Impact factor: 1.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.